Navigation Links
Watson Files Application for Generic SEASONIQUE(R)
Date:3/4/2008

CORONA, Calif., March 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. Watson's levonorgestrel and ethinyl estradiol product is a generic version of Barr's SEASONIQUE(R).

On January 23, 2008 pursuant to the Hatch-Waxman Act, Watson notified Barr that it had filed an ANDA with a paragraph IV certification with the FDA for a generic version of SEASONIQUE(R) asserting that the SEASONIQUE(R) patent is invalid or not infringed. Based on available information, Watson believes it may be the first applicant to file an ANDA for SEASONIQUE(R) and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

SEASONIQUE(R) is indicated for the prevention of pregnancy.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

SEASONIQUE(R) is a registered trademark of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2018)... ... November 16, 2018 , ... OnlineMasters.com, an ... Educational Psychology Programs for 2019. They have identified the top programs in the ... affordability, and graduate outcomes. , Leveraging an exclusive data set comprised of interviews ...
(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... ... and cosmetic benefits of acupuncture available to people in an accessible and affordable ... and wellness franchise in the nation, opening locations all across the country. , ...
(Date:11/15/2018)... ... 2018 , ... Over the last decade, SABRE , the global leader ... National Breast Cancer Foundation (NBCF) . A mission-driven organization and proud partner of ... have helped launch the National Mammography Program which has provided almost 300,000 ...
(Date:11/15/2018)... ... November 15, 2018 , ... Mothers ... thanks to a unique collaboration that puts vital health education resources right at ... Shield of California Promise Health Plan effective 1/1/19), an affiliate of Blue Shield ...
(Date:11/15/2018)... Texas (PRWEB) , ... November 15, 2018 , ... ... the latest version of its paperless, web-based eForms solution for hospitals . ... and enables users to launch eForms directly from any of these systems, have ...
Breaking Medicine News(10 mins):
(Date:11/16/2018)... ... November 16, 2018 , ... Dr. Michael Goldberger of the Foot & Ankle ... as well as new winter shoes to the area’s homeless in collaboration with his team ... second year the event will take place at the Isaiah House, located at 238 N. ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... Dry Shampoo Collection that quickly refreshes and restores hair between washes. , ... comprised of three different products, including an instant drying foam that can be ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... engaged as exclusive financial advisor on a $2 million convertible note investment ... field. Toolbox Genomics is dedicated to becoming the healthcare industry’s gold standard ...
Breaking Medicine Technology: